Sensex Finishes Over 240 Points Higher; Metal & Healthcare Stocks Gain Most

Wed, 19 Jul Closing

   Previous Close   

   Pre-Open   

   09:30 am   

   11:30 am   

   01:30 pm   

Share markets in India continued their upward climb in afternoon trade. At the closing bell, the BSE Sensex closed higher by 244 points. While, the NSE Nifty finished higher by 72 points. Meanwhile, the <>S&P BSE Midcap Index andthe S&P BSE Small Cap Index both ended up by 1%.

All sectoral indices finished the day in green with metal sector and healthcare sector witnessing maximum buying interest.

Asian equity markets finished broadly higher today with shares in China leading the region. The Shanghai Composite is up 1.36% while Hong Kong's Hang Seng is up 0.56% and Japan's Nikkei 225 is up 0.10%. European markets are higher today with shares in London leading the region. The FTSE 100 is up 0.11% while France's CAC 40 is up 0.09% and Germany's DAX is up 0.04%.

The rupee was trading at Rs 64.32 against the US$ in the afternoon session. Oil prices were trading at US$ 46.71 at the time of writing.

Pharma stocks closed the day on a positive note with Aurobindo Pharma and Wockhardt leading the gains. Aurobindo Pharma share price soaredover 4.5% after the company received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800mg.

Sevelamer Carbonate tablets are a therapeutic equivalent generic version of Genzyme's Renvela tablets and is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

The approved product has an estimated market size of US$1.9 billion for the twelve months ending May 2017, according to IMS.

In another development, Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2g in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda.

Reportedly, this is currently the only generic available to patients in the US.

Lately, pharmaceutical companies have been facing a surfeit of problems in the largest generic market, the US. Rising competition and consolidation in the distribution channel have led to price erosion and delayed approvals for them.

Once considered a safe haven for investors has been on a steady decline over the past two years.

The list of pharma sector woes (subscription required) is long. But, is there light at the end of the tunnel? Girish Shetty, our pharma analyst thinks there is.

As per him, it doesn't make sense to paint all pharma stocks with the same brush. The leaders of the industry will certainly survive this phase. And just like IT, there are interesting, niche pharma stocks that are worth your attention.

So, what is key to identifying potential multibagger stocks? How does one pick them at the right time and ride them to their full potential? How many multibaggers do you really need to achieve the big riches that you desire?

Most importantly, are there any stocks right now that could turn out to be multibaggers? Click here to know everything that you need to know right now about mutlibagger stocks...

Cadila Healthcare share price finished up by 3.7%.

Moving on to the news from the economy. Global ratings agency Fitch Ratings in its latest report on impact of Goods and Services Tax (GST) on different sectors, has said that the new indirect tax regime is likely to be beneficial for auto, cement and organised retail sectors.

However,it will have a negative impact on oil and gas, and SME sectors. It further said that the impact would be broadly neutral for property, electricity, telecom, pharmaceutical and fertiliser sectors.

GST's Impact on Aam Aadmi's Spending

The rating agency pointed that under the Indian GST regime, a corporate will only be able to apply GST input tax credits after its supplier of goods or services has first settled its GST payment with the government.

This means that the burden of non-compliance by the supplier will rest with the purchaser and not the government. Further, GST tax truancy by financially weak and non-compliant companies lower down the supply chain could limit the amount of input tax credits available for the larger and financially strong corporate.

Also, as Rahul Shah, co-head of research, is of opinion that the positives will far outweigh the negatives in the long term. Here's an excerpt of what he wrote in the recent edition of The 5 Minute WrapUp:

• "All of this is formalisation in action. Formalisation is good for the economy, good for consumers, and good for the government too. In fact, it is a long-term positive for all stakeholders. And if everyone benefits, stock markets can't be far behind."

The process, however, certainly won't be glitch-free. There will be pain in the short term as the informal economy could see job losses and decreased demand.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers